Tiaopi huxin recipe improved endothelial dysfunction and attenuated atherosclerosis by decreasing the expression of caveolin‐1 in ApoE‐deficient mice

The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclero...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular physiology Vol. 234; no. 9; pp. 15369 - 15379
Main Authors Wen, Junmao, Lin, Tong, Wu, Wei, Yang, Yi, Luo, Chuanjin, Zhou, Chi, Wan, Jindong, Liu, Sen, Wang, Dan, Wang, Peijian, Li, Junzhe
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.09.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE−/−) mice were fed a high‐fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low‐dose, medium‐dose, and high‐dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein‐2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), hs‐CRP, IL‐6, and IL‐1β, in mice plasma were analyzed by enzyme‐linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high‐ and medium‐dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE −/− mice. The high‐ and medium‐dose TPHXR treatment, but not the low‐dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium‐dependent vasorelaxation in ApoE −/− mice. High‐ and medium‐dose TPHXR, but not low‐dose TPHXR, decreased the expression of cav‐1, NF‐κB p50, NF‐κB p65, ICAM1, VCAM‐1, TNF‐α, IL‐6, and IL‐1β in the vasculature of ApoE −/− mice. Enzyme‐linked immunosorbent assay analysis indicated that high‐ and medium‐dose TPHXR decreased the levels of TNF‐α, IL‐6, hs‐CRP, and IL‐1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE −/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS. Our findings show that tiaopi huxin recipe (TPHXR) improved the endothelial function and reduced atheromatous lesions in ApoE−/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in atherosclerosis mice vasculature. TPHXR may represent a promising intervention in patients with artherosclerosis.
AbstractList The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE ) mice were fed a high-fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low-dose, medium-dose, and high-dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein-2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor-α (TNF-α), hs-CRP, IL-6, and IL-1β, in mice plasma were analyzed by enzyme-linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high- and medium-dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE mice. The high- and medium-dose TPHXR treatment, but not the low-dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium-dependent vasorelaxation in ApoE mice. High- and medium-dose TPHXR, but not low-dose TPHXR, decreased the expression of cav-1, NF-κB p50, NF-κB p65, ICAM1, VCAM-1, TNF-α, IL-6, and IL-1β in the vasculature of ApoE mice. Enzyme-linked immunosorbent assay analysis indicated that high- and medium-dose TPHXR decreased the levels of TNF-α, IL-6, hs-CRP, and IL-1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE mice. This result may be due to the decreased expression of caveolin-1 and NF-κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS.
Abstract The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE −/− ) mice were fed a high‐fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low‐dose, medium‐dose, and high‐dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein‐2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), hs‐CRP, IL‐6, and IL‐1β, in mice plasma were analyzed by enzyme‐linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high‐ and medium‐dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE −/− mice. The high‐ and medium‐dose TPHXR treatment, but not the low‐dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium‐dependent vasorelaxation in ApoE −/− mice. High‐ and medium‐dose TPHXR, but not low‐dose TPHXR, decreased the expression of cav‐1, NF‐κB p50, NF‐κB p65, ICAM1, VCAM‐1, TNF‐α, IL‐6, and IL‐1β in the vasculature of ApoE −/− mice. Enzyme‐linked immunosorbent assay analysis indicated that high‐ and medium‐dose TPHXR decreased the levels of TNF‐α, IL‐6, hs‐CRP, and IL‐1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE −/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS.
The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE−/−) mice were fed a high‐fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low‐dose, medium‐dose, and high‐dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein‐2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), hs‐CRP, IL‐6, and IL‐1β, in mice plasma were analyzed by enzyme‐linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high‐ and medium‐dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE −/− mice. The high‐ and medium‐dose TPHXR treatment, but not the low‐dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium‐dependent vasorelaxation in ApoE −/− mice. High‐ and medium‐dose TPHXR, but not low‐dose TPHXR, decreased the expression of cav‐1, NF‐κB p50, NF‐κB p65, ICAM1, VCAM‐1, TNF‐α, IL‐6, and IL‐1β in the vasculature of ApoE −/− mice. Enzyme‐linked immunosorbent assay analysis indicated that high‐ and medium‐dose TPHXR decreased the levels of TNF‐α, IL‐6, hs‐CRP, and IL‐1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE −/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS. Our findings show that tiaopi huxin recipe (TPHXR) improved the endothelial function and reduced atheromatous lesions in ApoE−/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in atherosclerosis mice vasculature. TPHXR may represent a promising intervention in patients with artherosclerosis.
The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE−/−) mice were fed a high‐fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low‐dose, medium‐dose, and high‐dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein‐2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), hs‐CRP, IL‐6, and IL‐1β, in mice plasma were analyzed by enzyme‐linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high‐ and medium‐dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE−/− mice. The high‐ and medium‐dose TPHXR treatment, but not the low‐dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium‐dependent vasorelaxation in ApoE−/− mice. High‐ and medium‐dose TPHXR, but not low‐dose TPHXR, decreased the expression of cav‐1, NF‐κB p50, NF‐κB p65, ICAM1, VCAM‐1, TNF‐α, IL‐6, and IL‐1β in the vasculature of ApoE−/− mice. Enzyme‐linked immunosorbent assay analysis indicated that high‐ and medium‐dose TPHXR decreased the levels of TNF‐α, IL‐6, hs‐CRP, and IL‐1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE−/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS.
Author Lin, Tong
Li, Junzhe
Zhou, Chi
Wang, Dan
Wu, Wei
Luo, Chuanjin
Liu, Sen
Wen, Junmao
Wan, Jindong
Yang, Yi
Wang, Peijian
Author_xml – sequence: 1
  givenname: Junmao
  surname: Wen
  fullname: Wen, Junmao
  organization: Guangzhou University of Chinese Medicine
– sequence: 2
  givenname: Tong
  surname: Lin
  fullname: Lin, Tong
  organization: Guangzhou University of Chinese Medicine
– sequence: 3
  givenname: Wei
  surname: Wu
  fullname: Wu, Wei
  organization: First Affiliated Hospital of Guangzhou University of Chinese Medicine
– sequence: 4
  givenname: Yi
  surname: Yang
  fullname: Yang, Yi
  organization: The First Affiliated Hospital, Chengdu Medical College
– sequence: 5
  givenname: Chuanjin
  surname: Luo
  fullname: Luo, Chuanjin
  organization: First Affiliated Hospital of Guangzhou University of Chinese Medicine
– sequence: 6
  givenname: Chi
  surname: Zhou
  fullname: Zhou, Chi
  organization: First Affiliated Hospital of Guangzhou University of Chinese Medicine
– sequence: 7
  givenname: Jindong
  surname: Wan
  fullname: Wan, Jindong
  organization: The First Affiliated Hospital, Chengdu Medical College
– sequence: 8
  givenname: Sen
  surname: Liu
  fullname: Liu, Sen
  organization: The First Affiliated Hospital, Chengdu Medical College
– sequence: 9
  givenname: Dan
  surname: Wang
  fullname: Wang, Dan
  organization: The First Affiliated Hospital, Chengdu Medical College
– sequence: 10
  givenname: Peijian
  surname: Wang
  fullname: Wang, Peijian
  email: wpjmed@aliyun.com
  organization: The First Affiliated Hospital, Chengdu Medical College
– sequence: 11
  givenname: Junzhe
  orcidid: 0000-0002-3988-542X
  surname: Li
  fullname: Li, Junzhe
  email: 2015404734@qq.com
  organization: Guangdong Hospital of Chinese Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30729525$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1u1DAQxy1URLcLB14AWeICh7T-iLfxsVqVL1WCQzlHznjMepXYwU5K98YjcOX1-iT1dgsHJKTRzEjz898e_0_IUYgBCXnJ2SlnTJxtYTwVDW_qJ2TBmT6v6pUSR2RRZrzSqubH5CTnLWNMaymfkWPJzoVWQi3I72tv4ujpZr71gSYEPyL1w5jiDVqKwcZpg703PbW77OYAk4-BmmCpmSYMs5lw324wxQz9PvtMux21CAlN9uEbLUOKt2PCnPdno6NgbjD2Ptz9_MVpufZijJelt-g8eAwTHTzgc_LUmT7ji8e6JF_fXV6vP1RXn99_XF9cVSCVrCt0yMFZLRoFdiWdqVdN11m34kZY4TQoYZB1TnPUTtdKMwVNLUF16Ay4Ti7Jm4Nu2fn7jHlqB58B-94EjHNuhRCaaa6ZKOjrf9BtnFMor3ugGsVliSV5e6Cg_EZO6Nox-cGkXctZu_erLX61D34V9tWj4twNaP-SfwwqwNkB-OF73P1fqf20_nKQvAdHlqce
CitedBy_id crossref_primary_10_1016_j_heliyon_2023_e18653
crossref_primary_10_1080_21691401_2019_1646264
crossref_primary_10_1155_2022_1852330
crossref_primary_10_14336_AD_2019_09603
crossref_primary_10_3389_fphar_2020_546825
crossref_primary_10_1155_2020_8683404
crossref_primary_10_3748_wjg_v26_i10_1029
Cites_doi 10.1016/j.atherosclerosis.2015.04.783
10.3892/ijmm.2014.1646
10.3390/ijms18061260
10.1016/j.cmet.2009.06.003
10.1159/000486155
10.1016/j.cardiores.2007.04.012
10.2174/138161212802481237
10.1161/CIRCULATIONAHA.109.192666
10.1159/000131083
10.1146/annurev.physiol.64.081501.155952
10.1172/JCI11871
10.1159/000374074
10.13193/j.issn.1673‐7717.2014.10.052
10.1016/j.amjcard.2007.02.001
10.3969/j.issn.1004‐745X.2015.12.067
10.1097/00041433-200410000-00005
10.1097/MCA.0000000000000082
10.7501/j.issn.1674‐6376.2013.04.016
10.1161/01.ATV.21.2.201
10.1038/82176
10.1074/jbc.271.44.27237
10.1161/01.ATV.0000101182.89118.E5
10.1016/j.jacc.2016.11.005
10.1111/j.1365‐2796.2006.01621.x
10.1007/s11655‐012‐1123‐x
10.1159/000370010
10.1038/35025203
10.1161/STR.0b013e3181fcb238
10.4268/cjcmm20120723
10.1161/HYPERTENSIONAHA.115.06223
10.1016/j.ijcard.2007.08.077
10.1007/s00441‐013‐1767‐7
10.1016/S0140‐6736(17)32247‐X
ContentType Journal Article
Copyright 2019 Wiley Periodicals, Inc.
Copyright_xml – notice: 2019 Wiley Periodicals, Inc.
DBID NPM
AAYXX
CITATION
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
7X8
DOI 10.1002/jcp.28184
DatabaseName PubMed
CrossRef
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
Genetics Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList PubMed
CrossRef

Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Biology
EISSN 1097-4652
EndPage 15379
ExternalDocumentID 10_1002_jcp_28184
30729525
JCP28184
Genre article
Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  funderid: 81403225; 81400289
– fundername: The training project of Top‐notch Creative Talents of Guangzhou University of Chinese Medicine
  funderid: BKBJCX2018003
– fundername: Program of Sichuan Youth Science and Technology Foundation in China
  funderid: 2016JQ0032
– fundername: the Innovation Team Project Department of Education of Sichuan Province
  funderid: 18TD0030
– fundername: National Natural Science Foundation of China
  grantid: 81400289
– fundername: the Innovation Team Project Department of Education of Sichuan Province
  grantid: 18TD0030
– fundername: The training project of Top-notch Creative Talents of Guangzhou University of Chinese Medicine
  grantid: BKBJCX2018003
– fundername: Program of Sichuan Youth Science and Technology Foundation in China
  grantid: 2016JQ0032
– fundername: National Natural Science Foundation of China
  grantid: 81403225
GroupedDBID ---
-DZ
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
36B
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
9M8
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEFU
ABEML
ABIJN
ABJNI
ABPPZ
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACNCT
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AETEA
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BQCPF
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
G8K
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
H~9
IH2
IX1
J0M
JPC
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M56
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MVM
MXFUL
MXSTM
N04
N05
N9A
NEJ
NF~
NNB
O66
O9-
OHT
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RWR
RX1
RYL
S10
SAMSI
SUPJJ
SV3
TN5
TWZ
UB1
UPT
V2E
V8K
VQP
W8V
W99
WBKPD
WH7
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WXSBR
WYB
WYISQ
X7M
XG1
XJT
XOL
XPP
XSW
XV2
Y6R
YQT
YZZ
ZGI
ZXP
ZZTAW
~IA
~WT
NPM
AAYXX
CITATION
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c3534-efe1cfd9285cd63fa468bbdf61a2d2f9c52ae0bf91e9f945905c843c5befacfb3
IEDL.DBID DR2
ISSN 0021-9541
IngestDate Fri Aug 16 09:46:24 EDT 2024
Sat Oct 26 04:14:34 EDT 2024
Thu Sep 26 20:25:19 EDT 2024
Sat Sep 28 08:17:00 EDT 2024
Sat Aug 24 01:17:55 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords atherosclerosis
caveolin-1
tiaopi huxin recipe
inflammation
endothelial dysfunction
Language English
License 2019 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3534-efe1cfd9285cd63fa468bbdf61a2d2f9c52ae0bf91e9f945905c843c5befacfb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-3988-542X
PMID 30729525
PQID 2229851351
PQPubID 1006363
PageCount 11
ParticipantIDs proquest_miscellaneous_2229091902
proquest_journals_2229851351
crossref_primary_10_1002_jcp_28184
pubmed_primary_30729525
wiley_primary_10_1002_jcp_28184_JCP28184
PublicationCentury 2000
PublicationDate September 2019
2019-Sep
2019-09-00
20190901
PublicationDateYYYYMMDD 2019-09-01
PublicationDate_xml – month: 09
  year: 2019
  text: September 2019
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Journal of cellular physiology
PublicationTitleAlternate J Cell Physiol
PublicationYear 2019
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References e_1_2_8_1_12_1
e_1_2_8_1_11_1
e_1_2_8_1_36_1
e_1_2_8_1_14_1
e_1_2_8_1_33_1
e_1_2_8_1_13_1
e_1_2_8_1_34_1
Wang H. (e_1_2_8_1_31_1) 2008; 14
e_1_2_8_1_32_1
e_1_2_8_1_10_1
e_1_2_8_1_30_1
e_1_2_8_1_8_1
e_1_2_8_1_9_1
Zhang J. T. (e_1_2_8_1_35_1) 2015; 30
e_1_2_8_1_27_1
e_1_2_8_1_26_1
e_1_2_8_1_29_1
e_1_2_8_1_28_1
e_1_2_8_1_23_1
e_1_2_8_1_22_1
e_1_2_8_1_25_1
e_1_2_8_1_21_1
e_1_2_8_1_20_1
e_1_2_8_1_2_1
e_1_2_8_1_3_1
e_1_2_8_1_6_1
e_1_2_8_1_7_1
e_1_2_8_1_4_1
e_1_2_8_1_5_1
e_1_2_8_1_19_1
e_1_2_8_1_16_1
e_1_2_8_1_39_1
e_1_2_8_1_15_1
Ma Y. (e_1_2_8_1_24_1) 2012; 18
e_1_2_8_1_18_1
e_1_2_8_1_37_1
e_1_2_8_1_17_1
e_1_2_8_1_38_1
References_xml – ident: e_1_2_8_1_17_1
  doi: 10.1016/j.atherosclerosis.2015.04.783
– ident: e_1_2_8_1_33_1
  doi: 10.3892/ijmm.2014.1646
– ident: e_1_2_8_1_34_1
  doi: 10.3390/ijms18061260
– ident: e_1_2_8_1_38_1
– ident: e_1_2_8_1_6_1
  doi: 10.1016/j.cmet.2009.06.003
– ident: e_1_2_8_1_25_1
  doi: 10.1159/000486155
– ident: e_1_2_8_1_19_1
  doi: 10.1016/j.cardiores.2007.04.012
– ident: e_1_2_8_1_29_1
  doi: 10.2174/138161212802481237
– ident: e_1_2_8_1_21_1
  doi: 10.1161/CIRCULATIONAHA.109.192666
– ident: e_1_2_8_1_5_1
  doi: 10.1159/000131083
– ident: e_1_2_8_1_28_1
  doi: 10.1146/annurev.physiol.64.081501.155952
– ident: e_1_2_8_1_4_1
  doi: 10.1172/JCI11871
– ident: e_1_2_8_1_30_1
  doi: 10.1159/000374074
– ident: e_1_2_8_1_18_1
  doi: 10.13193/j.issn.1673‐7717.2014.10.052
– volume: 18
  start-page: 140
  year: 2012
  ident: e_1_2_8_1_24_1
  article-title: Effects of serum containing tanyu tongzhi fang on expression of NF‐κB and ICAM‐1 in HUVECs injured by ox‐LDL
  publication-title: Chinese Journal of Experimental Traditional Medical Formulae
  contributor:
    fullname: Ma Y.
– ident: e_1_2_8_1_7_1
  doi: 10.1016/j.amjcard.2007.02.001
– ident: e_1_2_8_1_37_1
  doi: 10.3969/j.issn.1004‐745X.2015.12.067
– ident: e_1_2_8_1_8_1
  doi: 10.1097/00041433-200410000-00005
– ident: e_1_2_8_1_14_1
  doi: 10.1097/MCA.0000000000000082
– ident: e_1_2_8_1_36_1
  doi: 10.7501/j.issn.1674‐6376.2013.04.016
– ident: e_1_2_8_1_16_1
  doi: 10.1161/01.ATV.21.2.201
– ident: e_1_2_8_1_3_1
  doi: 10.1038/82176
– ident: e_1_2_8_1_10_1
  doi: 10.1074/jbc.271.44.27237
– volume: 14
  start-page: 598
  year: 2008
  ident: e_1_2_8_1_31_1
  article-title: Vascular endothelial and atherosclerosis
  publication-title: Medical Recapitulate
  contributor:
    fullname: Wang H.
– ident: e_1_2_8_1_9_1
  doi: 10.1161/01.ATV.0000101182.89118.E5
– ident: e_1_2_8_1_2_1
  doi: 10.1016/j.jacc.2016.11.005
– ident: e_1_2_8_1_13_1
  doi: 10.1111/j.1365‐2796.2006.01621.x
– ident: e_1_2_8_1_15_1
  doi: 10.1007/s11655‐012‐1123‐x
– ident: e_1_2_8_1_20_1
  doi: 10.1159/000370010
– ident: e_1_2_8_1_22_1
  doi: 10.1038/35025203
– ident: e_1_2_8_1_39_1
– ident: e_1_2_8_1_12_1
  doi: 10.1161/STR.0b013e3181fcb238
– ident: e_1_2_8_1_23_1
  doi: 10.4268/cjcmm20120723
– ident: e_1_2_8_1_32_1
  doi: 10.1161/HYPERTENSIONAHA.115.06223
– ident: e_1_2_8_1_11_1
  doi: 10.1016/j.ijcard.2007.08.077
– ident: e_1_2_8_1_26_1
  doi: 10.1007/s00441‐013‐1767‐7
– ident: e_1_2_8_1_27_1
  doi: 10.1016/S0140‐6736(17)32247‐X
– volume: 30
  start-page: 4006
  year: 2015
  ident: e_1_2_8_1_35_1
  article-title: Overview about preparation methods of serum containing Chinese medicine
  publication-title: China Journal of Traditional Chinese Medicine and Pharmacy
  contributor:
    fullname: Zhang J. T.
SSID ssj0009933
Score 2.3821528
Snippet The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of...
Abstract The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 15369
SubjectTerms Aorta
Apolipoprotein E
Arteriosclerosis
Atherosclerosis
Cardiovascular disease
Cardiovascular diseases
Caveolin
caveolin‐1
Coronary artery disease
Cytokines
Endothelial cells
endothelial dysfunction
Endothelium
Enzymes
Heart diseases
Herbal medicine
High fat diet
Inflammation
Inflammatory response
Intercellular adhesion molecule 1
Lesions
Nitric oxide
Oils & fats
Phosphorylation
Plaques
Staining
tiaopi huxin recipe
Traditional Chinese medicine
Tumor necrosis factor
Tumor necrosis factor-TNF
Umbilical vein
Vasodilation
Title Tiaopi huxin recipe improved endothelial dysfunction and attenuated atherosclerosis by decreasing the expression of caveolin‐1 in ApoE‐deficient mice
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.28184
https://www.ncbi.nlm.nih.gov/pubmed/30729525
https://www.proquest.com/docview/2229851351
https://search.proquest.com/docview/2229091902
Volume 234
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9UwFD-MgeCLH5sf1SlRRHzpXds0vQ0-XebGGCgiG-xBKPlkVZcWeyu7Pvkn-Oq_51_iSdreMUUQX0ogaU-bnJP8cnryOwDP5hpRQCFErCRqcF4mNubKprFkiUKAwKkOh8RevykOT_KjU3a6AS-nszADP8Ta4eYtI8zX3sCF7HYvSUM_qHbmqYw8F2hK5z6c69W7S-ooPqaRDyEILE8nVqEk213feXUt-gNgXsWrYcE5uAnvp1cd4kw-zvqlnKmvv7E4_ue33IIbIxAli0FzbsOGcVuwvXC4CT9fkeckhIYGn_sWXBsyVq624cdxLZq2Jmf9Re2IZ8ZoDamDY8JoYpz2B7o-oU4Tver8munHnQiniefxdD0iW19ERWk6FIvXuiNyRXRAr95vQbCSmIsxPteRxhIlvhifW-jnt-8pQbGLttnHsjae_QIXTXKOs90dODnYP947jMfsDrGijOaxsSZVVvOsZEoX1Iq8KKXUtkhFpjPLFcuESaTlqeGW54wnTJU5VUwaK5SV9C5susaZ-0BK3EhSfJhMBQKknAo5F1SrOc43ObeZjeDpNM5VO5B4VANdc1Zh11eh6yPYmTSgGu24q3y2c8SklKURPFlXowX63yrCmaYf2iDq4kkWwb1Bc9ZSqCdmZxmL4EUY_7-Lr4723obCg39v-hCuI34bQ952YHP5uTePECMt5eNgDL8AgLoSZA
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB6VIgQXfloKgQIGIcQl2ySOs7HEZVVaLaWtENpKvaDIvyK0TSJ2F3U58QhceT2ehLGTbFUQEuISWbKTSewZ-_Nk_A3A86FGFJAJESqJGpzmkQ25snEoWaQQIHCq_SGxg8NsfJTuHbPjFXjVn4Vp-SGWDjdnGX6-dgbuHNJbF6yhn1QzcFxG6RW4iuZOXeKG1-8vyKN4l0jeByGwNO55haJka3nr5dXoD4h5GbH6JWf3FnzoX7aNNDkZzGdyoL7-xuP4v19zG252WJSMWuW5AyumWoP1UYX78LMFeUF8dKh3u6_BtTZp5WIdfkxKUTcl-Tg_LyviyDEaQ0rvmzCamEq7M12nqNZEL6Zu2XRDT0SliaPyrOYIbl0RdaWeoli8llMiF0R7AOtcFwQriTnvQnQrUluixBfj0gv9_PY9Jih21NQ7WNbGEWDguknOcMK7C0e7O5PtcdgleAgVZTQNjTWxsponOVM6o1akWS6ltlksEp1YrlgiTCQtjw23PGU8YipPqWLSWKGspBuwWtWVuQ8kx70kxYfJWCBGSqmQQ0G1GuKUk3Kb2ACe9QNdNC2PR9EyNicFdn3huz6AzV4Fis6Up4VLeI6wlLI4gKfLajRC92dFVKaet20QePEoCeBeqzpLKdRxs7OEBfDSK8DfxRd72-984cG_N30C18eTg_1i_83h24dwA-FcFwG3Cauzz3PzCCHTTD72lvELdbwWfA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIhAXHi2PhQIGIcQl2yS2s7E4rUpXpUBVoVbqASnyU6SlScTuoi4nfgJX_h6_hLGTbFUQEuISWbKTSewZ-_Nk_A3As5FBFJBJGWmFGszy2EVCuyRSPNYIEAQ14ZDYu71s55DtHvGjFXjZn4Vp-SGWDjdvGWG-9gbeGLd5Thp6rJuhpzJil-AyyxD5ekT0_pw7SnR55EMMAmdJTysUp5vLWy8uRn8gzIuANaw4kxvwoX_XNtDkZDifqaH--huN439-zE243iFRMm5V5xas2GoN1scV7sJPF-Q5CbGhwem-BlfalJWLdfhxUMq6KcnH-VlZEU-N0VhSBs-ENcRWxp_o-oRKTcxi6hdNP_BEVoZ4Is9qjtDWF1FT6imKxWs5JWpBTICv3nFBsJLYsy5AtyK1I1p-sT650M9v3xOCYsdNvY1lYz39Ba6a5BSnu9twONk-2NqJuvQOkaacssg6m2hnRJpzbTLqJMtypYzLEpma1AnNU2lj5URihROMi5jrnFHNlXVSO0XvwGpVV_YekBx3khQfphKJCIlRqUaSGj3CCYcJl7oBPO3HuWhaFo-i5WtOC-z6InT9ADZ6DSg6Q54WPt05glLKkwE8WVajCfr_KrKy9bxtg7BLxOkA7raas5RCPTM7T_kAXoTx_7v4YndrPxTu_3vTx3B1_9WkePt6780DuIZYrgt_24DV2ee5fYh4aaYeBbv4BTTPFSs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tiaopi+huxin+recipe+improved+endothelial+dysfunction+and+attenuated+atherosclerosis+by+decreasing+the+expression+of+caveolin-1+in+ApoE-deficient+mice&rft.jtitle=Journal+of+cellular+physiology&rft.au=Wen%2C+Junmao&rft.au=Lin%2C+Tong&rft.au=Wu%2C+Wei&rft.au=Yang%2C+Yi&rft.date=2019-09-01&rft.eissn=1097-4652&rft.volume=234&rft.issue=9&rft.spage=15369&rft.epage=15379&rft_id=info:doi/10.1002%2Fjcp.28184&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon